ESRP2 and neoplasm: Immunohistochemistry of ~19,000 prostate tumours correlated high levels of ESRP1 and ESRP2 protein expression with more rapid biochemical tumour recurrence, higher Gleason scores, higher tumour stages and increased numbers of lymph node metastases [28, 29, 31].